Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KITE-753 |
| Synonyms | |
| Therapy Description |
KITE-753 comprises autologous T-lymphocytes manufactured to preserve juvenile T-cells and engineered to express a chimeric antigen receptor (CAR) targeting CD19 containing a CD28 co-stimulatory domain and a CAR targeting CD20 with a 4-1BB co-stimulatory domain, which potentially decrease tumor growth (Blood (2025) 146 (Supplement 1): 704). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KITE-753 | KITE753|KITE 753 | CD19 Immune Cell Therapy 74 CD20 Immune Cell Therapy 16 | KITE-753 comprises autologous T-lymphocytes manufactured to preserve juvenile T-cells and engineered to express a chimeric antigen receptor (CAR) targeting CD19 containing a CD28 co-stimulatory domain and a CAR targeting CD20 with a 4-1BB co-stimulatory domain, which potentially decrease tumor growth (Blood (2025) 146 (Supplement 1): 704). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04989803 | Phase Ib/II | KITE-753 KITE-363 Cyclophosphamide + Fludarabine | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Recruiting | USA | NLD | GBR | DEU | AUS | 0 |